OncoTherapy Science, Inc. (DE:30O)

FRANKFURT:30O

30O

OncoTherapy Science

RESEARCH TOOLSreports

OncoTherapy Science (30O) Price & Analysis

0 Followers

30O Stock Chart & Stats

€0.11

>-€0.01(-4.03%)

At close: Jan 08 4:00 PM EST

€0.11

>-€0.01(-4.03%)

Day’s Range― - ―

52-Week Range€0.06 - €0.19

Previous CloseN/A

Volume0.00

Average Volume (3M)0.00

Market Cap

€56.02M

Enterprise Value€6.76B

Total Cash (Recent Filing)€1.23B

Total Debt (Recent Filing)€37.14M

Price to Earnings (P/E)―

Beta-0.09

Next Earnings

Jan 29, 2027

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)>-0.01

Shares Outstanding383,643,700

10 Day Avg. Volume0

30 Day Avg. Volume0

Financial Highlights & Ratios

PEG Ratio0.19

Price to Book (P/B)10.03

Price to Sales (P/S)9.75

P/FCF Ratio-8.97

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Oncology-focused R&D StrategyA clear, specialized focus on oncology and cancer genomics supports a durable business model: concentrated expertise increases odds of meaningful drug/diagnostic assets, attracts partner interest, and aligns with long-term demand for targeted cancer therapies, aiding strategic collaborations and licensing.

Relatively High Equity Ratio On Balance SheetA relatively high equity ratio provides a structural buffer versus insolvency risk and gives the company longer runway to develop assets. This balance-sheet strength supports ongoing R&D investment and makes the firm more attractive for non-dilutive partnerships or milestone financing over the medium term.

Positive Revenue And EPS Growth MetricsReported positive revenue growth (~10.9%) and EPS growth (~31.5%) indicate improving operational performance trends. Sustained top-line and per-share improvements can help justify continued R&D spend, improve partner negotiation leverage, and reduce reliance on frequent emergency financings if the trend persists.

Bears Say

Persistent Negative Operating And Free Cash FlowChronic negative operating and free cash flow is a fundamental constraint: the company must repeatedly access external financing to fund trials and development. This raises dilution and execution risk, and limits ability to self-fund pivotal studies or scale commercial activities without partners.

Consistent Unprofitability And Negative MarginsSustained negative gross and net margins and persistently negative EBIT/EBITDA indicate structural operational loss-making. This reduces internal cash generation potential, lengthens the path to profitability, and increases dependency on external capital or deal-making to reach commercialization.

Declining Assets/equity And Meaningful LiabilitiesA trend of declining assets and equity combined with significant liabilities erodes financial flexibility. Over the medium term this raises solvency concerns, can constrain R&D or partnering options, and increases the probability that future financing will be more costly or dilutive.

30O FAQ

What was OncoTherapy Science, Inc.’s price range in the past 12 months?

OncoTherapy Science, Inc. lowest stock price was €0.06 and its highest was €0.19 in the past 12 months.

What is OncoTherapy Science, Inc.’s market cap?

OncoTherapy Science, Inc.’s market cap is €56.02M.

When is OncoTherapy Science, Inc.’s upcoming earnings report date?

OncoTherapy Science, Inc.’s upcoming earnings report date is Jan 29, 2027 which is in 295 days.

How were OncoTherapy Science, Inc.’s earnings last quarter?

OncoTherapy Science, Inc. released its earnings results on Feb 06, 2026. The company reported -€0.003 earnings per share for the quarter, missing the consensus estimate of N/A by -€0.003.

Is OncoTherapy Science, Inc. overvalued?

According to Wall Street analysts OncoTherapy Science, Inc.’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does OncoTherapy Science, Inc. pay dividends?

OncoTherapy Science, Inc. does not currently pay dividends.

What is OncoTherapy Science, Inc.’s EPS estimate?

OncoTherapy Science, Inc.’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does OncoTherapy Science, Inc. have?

OncoTherapy Science, Inc. has 383,643,700 shares outstanding.

What happened to OncoTherapy Science, Inc.’s price movement after its last earnings report?

OncoTherapy Science, Inc. reported an EPS of -€0.003 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same 0%.

Which hedge fund is a major shareholder of OncoTherapy Science, Inc.?

Currently, no hedge funds are holding shares in DE:30O

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

OncoTherapy Science, Inc.

OncoTherapy Science, Inc. researches and develops anti-cancer medicines and therapies in Japan. Its clinical development product pipeline includes small-molecule drugs, such as OTS167, a maternal embryonic leucine zipper kinase inhibitor that is in Phase I/II clinical trials for the treatment of acute myeloid leukemia, as well as in Phase I clinical trials for the treatment of breast cancer; and OTS964, a T-LAK cell-originated protein kinase inhibitor for the treatment of various cancer diseases. The company's clinical development product pipeline also comprise cancer- specific peptide vaccines, including S-588410, which is in Phase III clinical trials for the treatment esophageal cancer, as well as in Phase II clinical trials for the treatment of bladder cancer; S-488210 that is in Phase I/II clinical trials for the treatment of head and neck cancer; and S-588210, which is in Phase I clinical trials for the treatment of solid tumor. In addition, it is developing antibody drugs consisting of OTSA101, which is in Phase I clinical trials for synovial sarcoma; and KHK6640, an anti-amyloid beta peptide antibody that is Phase I clinical trials for Alzheimer's disease. Further, the company provides contract analysis services. OncoTherapy Science, Inc. was founded in 2001 and is headquartered in Kawasaki, Japan.